Literature DB >> 28927893

MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression.

Markus V Heppt1, Joshua X Wang2, Denitsa M Hristova2, Zhi Wei3, Ling Li2, Brianna Evans2, Marilda Beqiri2, Samir Zaman2, Jie Zhang3, Martin Irmler4, Carola Berking5, Robert Besch5, Johannes Beckers6, Frank J Rauscher2, Rick A Sturm7, David E Fisher8, Meenhard Herlyn9, Mizuho Fukunaga-Kalabis10.   

Abstract

Melanoma cells share many biological properties with neural crest stem cells. Here we show that the homeodomain transcription factor MSX1, which is significantly correlated with melanoma disease progression, reprograms melanocytes and melanoma cells toward a neural crest precursor-like state. MSX1-reprogrammed normal human melanocytes express the neural crest marker p75 and become multipotent. MSX1 induces a phenotypic switch in melanoma, which is characterized by an oncogenic transition from an E-cadherin-high nonmigratory state toward a ZEB1-high invasive state. ZEB1 up-regulation is responsible for the MSX1-induced migratory phenotype in melanoma cells. Depletion of MSX1 significantly inhibits melanoma metastasis in vivo. These results show that neural crest-like reprogramming achieved by a single factor is a critical process for melanoma progression.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28927893      PMCID: PMC5902795          DOI: 10.1016/j.jid.2017.05.038

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  36 in total

1.  Msx1 and Pax3 cooperate to mediate FGF8 and WNT signals during Xenopus neural crest induction.

Authors:  Anne-Hélène Monsoro-Burq; Estee Wang; Richard Harland
Journal:  Dev Cell       Date:  2005-02       Impact factor: 12.270

2.  A dermal niche for multipotent adult skin-derived precursor cells.

Authors:  Karl J L Fernandes; Ian A McKenzie; Pleasantine Mill; Kristen M Smith; Mahnaz Akhavan; Fanie Barnabé-Heider; Jeff Biernaskie; Adrienne Junek; Nao R Kobayashi; Jean G Toma; David R Kaplan; Patricia A Labosky; Victor Rafuse; Chi-Chung Hui; Freda D Miller
Journal:  Nat Cell Biol       Date:  2004-11       Impact factor: 28.824

3.  A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Authors:  Alexander Roesch; Mizuho Fukunaga-Kalabis; Elizabeth C Schmidt; Susan E Zabierowski; Patricia A Brafford; Adina Vultur; Devraj Basu; Phyllis Gimotty; Thomas Vogt; Meenhard Herlyn
Journal:  Cell       Date:  2010-05-14       Impact factor: 41.582

4.  Altered molecular pathways in melanocytic lesions.

Authors:  Maria Scatolini; Maurizia Mello Grand; Enrico Grosso; Tiziana Venesio; Alberto Pisacane; Antonella Balsamo; Roberta Sirovich; Mauro Risio; Giovanna Chiorino
Journal:  Int J Cancer       Date:  2010-04-15       Impact factor: 7.396

5.  microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family.

Authors:  T J Hemesath; E Steingrímsson; G McGill; M J Hansen; J Vaught; C A Hodgkinson; H Arnheiter; N G Copeland; N A Jenkins; D E Fisher
Journal:  Genes Dev       Date:  1994-11-15       Impact factor: 11.361

6.  Isolation of multipotent adult stem cells from the dermis of mammalian skin.

Authors:  J G Toma; M Akhavan; K J Fernandes; F Barnabé-Heider; A Sadikot; D R Kaplan; F D Miller
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

7.  The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma.

Authors:  Edgar Selzer; Volker Wacheck; Trevor Lucas; Elisabeth Heere-Ress; Min Wu; Katherine N Weilbaecher; Werner Schlegel; Peter Valent; Fritz Wrba; Hubert Pehamberger; David Fisher; Burkhard Jansen
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

8.  Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.

Authors:  Ossia M Eichhoff; Ashani Weeraratna; Marie C Zipser; Laurence Denat; Daniel S Widmer; Mai Xu; Lydia Kriegl; Thomas Kirchner; Lionel Larue; Reinhard Dummer; Keith S Hoek
Journal:  Pigment Cell Melanoma Res       Date:  2011-06-09       Impact factor: 4.693

9.  Active Notch1 confers a transformed phenotype to primary human melanocytes.

Authors:  Chelsea C Pinnix; John T Lee; Zhao-Jun Liu; Ronan McDaid; Klara Balint; Levi J Beverly; Patricia A Brafford; Min Xiao; Benjamin Himes; Susan E Zabierowski; Yumi Yashiro-Ohtani; Katherine L Nathanson; Ana Bengston; Pamela M Pollock; Ashani T Weeraratna; Brian J Nickoloff; Warren S Pear; Anthony J Capobianco; Meenhard Herlyn
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

10.  ZEB1 Regulates Multiple Oncogenic Components Involved in Uveal Melanoma Progression.

Authors:  Yao Chen; Xiaoqin Lu; Diego E Montoya-Durango; Yu-Hua Liu; Kevin C Dean; Douglas S Darling; Henry J Kaplan; Douglas C Dean; Ling Gao; Yongqing Liu
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

View more
  13 in total

1.  LINC01021 maintains tumorigenicity by enhancing N6-methyladenosine reader IMP2 dependent stabilization of MSX1 and JARID2: implication in colorectal cancer.

Authors:  Huizhe Wu; Xiangyu Ding; Xiaoyun Hu; Qing Zhao; Qiuchen Chen; Tong Sun; Yalun Li; Hao Guo; Meng Li; Ziming Gao; Weifan Yao; Lin Zhao; Kai Li; Minjie Wei
Journal:  Oncogene       Date:  2022-02-16       Impact factor: 9.867

2.  Developmental chromatin programs determine oncogenic competence in melanoma.

Authors:  Arianna Baggiolini; Scott J Callahan; Lorenz Studer; Richard M White; Emily Montal; Joshua M Weiss; Tuan Trieu; Mohita M Tagore; Sam E Tischfield; Ryan M Walsh; Shruthy Suresh; Yujie Fan; Nathaniel R Campbell; Sarah C Perlee; Nathalie Saurat; Miranda V Hunter; Theresa Simon-Vermot; Ting-Hsiang Huang; Yilun Ma; Travis Hollmann; Satish K Tickoo; Barry S Taylor; Ekta Khurana; Richard P Koche
Journal:  Science       Date:  2021-09-03       Impact factor: 63.714

Review 3.  Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.

Authors:  Ion G Motofei
Journal:  Curr Treat Options Oncol       Date:  2019-05-06

Review 4.  Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?

Authors:  Anja Wessely; Theresa Steeb; Ulrike Leiter; Claus Garbe; Carola Berking; Markus Vincent Heppt
Journal:  Int J Mol Sci       Date:  2020-12-06       Impact factor: 5.923

5.  Single-Cell RNA Sequencing Unravels Heterogeneity of the Stromal Niche in Cutaneous Melanoma Heterogeneous Spheroids.

Authors:  Jiří Novotný; Karolína Strnadová; Barbora Dvořánková; Šárka Kocourková; Radek Jakša; Pavel Dundr; Václav Pačes; Karel Smetana; Michal Kolář; Lukáš Lacina
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

6.  A Novel Apoptosis-Related Gene Signature Predicts Biochemical Recurrence of Localized Prostate Cancer After Radical Prostatectomy.

Authors:  Qijie Zhang; Kai Zhao; Lebin Song; Chengjian Ji; Rong Cong; Jiaochen Luan; Xiang Zhou; Jiadong Xia; Ninghong Song
Journal:  Front Genet       Date:  2020-11-30       Impact factor: 4.599

Review 7.  How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.

Authors:  Anja Wessely; Theresa Steeb; Carola Berking; Markus Vincent Heppt
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 8.  A narrative review of the roles of muscle segment homeobox transcription factor family in cancer.

Authors:  Chao Liu; Mengxi Huang; Chao Han; Huiyu Li; Jing Wang; Yadi Huang; Yanyan Chen; Jialong Zhu; Gongbo Fu; Hanqing Yu; Zengjie Lei; Xiaoyuan Chu
Journal:  Ann Transl Med       Date:  2021-05

Review 9.  Cell Adhesion Molecules in Plasticity and Metastasis.

Authors:  Jessica A Smart; Julia E Oleksak; Edward J Hartsough
Journal:  Mol Cancer Res       Date:  2020-10-01       Impact factor: 6.333

10.  Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts.

Authors:  Lionel Larribère; Silke Kuphal; Christos Sachpekidis; Laura Hüser; Anja Bosserhoff; Jochen Utikal
Journal:  Cancers (Basel)       Date:  2018-11-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.